Gene-Modified EBV-Specific T-Cell Therapy for EBV-Positive Hodgkin and Non-Hodgkin Lymphoma Including TNK-Lymphoproliferative Disease with or without Chemotherapy

What this Trial Is About

Researchers are evaluating a treatment for patients with Hodgkin or non-Hodgkin Lymphoma or TNK-lymphoproliferative disease that has returned or not improved after prior treatments. Many patients with these diseases have cancer cells infected by the Epstein Barr virus EBV, which can help the cancer evade the immune system. This study aims to find the highest safe dose of specially modified T cells that target EBV-infected cells and to assess how long these cells survive in the body and their effect on the cancer. Participants will provide blood to create C7R-EBV T cells, which are modified T cells made to live longer by adding a gene called C7R. Patients are assigned a dose of these cells based on their size. Some may receive chemotherapy with cyclophosphamide and fludarabine before the T cell infusion to prepare their body for the treatment. The T cells are given through an IV, and patients will be monitored closely in the clinic or hospital for side effects. If needed, patients may receive a second infusion of the T cells after at least six weeks. During the study, participants will have physical exams, blood tests, and imaging scans to track their cancer and monitor safety. Extra blood samples will be taken at specific times to study the T cells in the body, with follow-up visits continuing annually for up to 15 years to watch for long-term effects. Patients will also receive supportive care for any side effects or complications. Total participation may last many years due to long-term monitoring.

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma